Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi-Aventis To Expand Operations In China

This article was originally published in PharmAsia News

Executive Summary

France's Sanofi-Aventis plans to use a new agreement with the Shanghai Institute for Biological Sciences to expand its research and development facility and step up that work in China. The agreement calls for a focus on discovering and developing drugs to treat cancer, diabetes, and problems of the nervous systems. The agreement in Shanghai coincides with completion by the end of this year of the firm's biometrics center in Beijing, aimed at providing support for global and local clinical trials. (Click here for more

You may also be interested in...

Pharmaceutical Industry Examines China R&D Strategy Amidst Financial Crisis

In the face of sliding profit margins and imminent drug patent expiry, multinational drug firms are seeking different avenues such as investing in or buying biotech firms to acquire new drugs. Sanofi-Aventis does not discount such possibilities but advocates collaboration as a better model to retain talent and technology. The company recently established a partnership with the Shanghai Institute for Biological Sciences (PharmAsia News Oct. 23, 2008) to cooperate with local academic institutes instead of setting up its own R&D center. According to Sanofi officials, the firm's R&D investment this year will be flat or even decrease slightly. (Click here for more - Chinese Language)

‘Wrong Move’: Gottlieb Blasts Azar’s Perceived Regulatory Power Play Over FDA; HHS On Defense

The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”

US FDA Races To List Essential Medicines For Domestic Manufacture By White House Deadline

With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts